The Scope Fluidics Group, a life science company listed on the Warsaw Stock Exchange and developing innovative technologies for the medical diagnostics and healthcare markets, held over PLN 156.9 million in cash at the end of 2025, including approximately PLN 63.8 million in investment fund units. In October 2025, the Group raised over PLN 64 million gross through a share issue.
In 2025, the Group signed an agreement with an industry-recognized transaction advisor – U.S.-based Perella Weinberg Partners – marking the next stage in the process of securing a global business partner for the BACTEROMIC system. An international Clinical Advisory Board was also established to support the development of the BACTEROMIC system.
After the reporting period, in February this year, Bacteromic received IVDR certification for the system with the UNI Panel, enabling the Group to introduce the solution to the European market and strengthening its commercial potential. The company also submitted documentation initiating the IVDR certification process for the BACTEROMIC system with the UNI FAST Panel.
“2025 was a year of consistent value creation in medical technologies for Scope Fluidics. We confirmed that our operating model is systematically bringing us closer to the next key stages in the Group’s development. Our key project remains BACTEROMIC – an AST system which, in our view, is currently one of the most complete and market-ready diagnostic solutions available. During the past year, we focused on its further development and preparation for market entry. Our engagement with transaction advisor Perella Weinberg Partners and the establishment of the international Clinical Advisory Board strengthened the project’s potential ahead of future discussions regarding a strategic transaction. An important milestone was also the CE IVDR certification obtained in early 2026 for the BACTEROMIC system with the UNI Panel, confirming its readiness for commercialization in Europe and selected international markets. At the same time, we signed our first distribution agreements in Turkey and Romania. We also continued to develop Scope Discovery, which remains a source of new technological initiatives. Our activities are aligned with a long-term vision of building a strong center of medical innovation in Poland with global relevance. We believe that the technologies we are developing can have a real impact on the quality of diagnostics and treatment. We know that it is possible to build projects in Poland that can compete globally. In 2026, we will focus on the M&A process for the BACTEROMIC project, the launch of sales of the BACTEROMIC system, and the further expansion of our project portfolio,” said Piotr Garstecki, CEO of Scope Fluidics.
Scope Fluidics’ transaction advisor is Perella Weinberg Partners (PWP) – a global, independent advisory firm with over 700 employees across 10 offices. Since its founding, it has advised on transactions totaling over USD 1 trillion, including over USD 200 billion in healthcare since 2011. Its healthcare team comprises more than 65 specialists, including 9 partners, and PWP has extensive experience in the AST sector, having supported numerous successful transactions.
Bacteromic has established an international Clinical Advisory Board to support the development of the BACTEROMIC system. Experts from the United Kingdom, Italy, and the United States will help tailor the solution to clinical and market needs, supporting further technological development and its commercialization in international markets.
At the same time, the Group intensified its regulatory activities. In 2025, IVDR documentation was submitted for the BACTEROMIC system with the UNI Panel, and collaboration on FDA certification for the UNI FAST Panel was expanded. In early 2026, the system received CE IVDR certification, enabling its sale in Europe and other countries recognizing this certification. The certification covers the UNI Panel (30 antibiotics, 56 combinations) and the entire system, confirming the maturity of the technology. The IVDR certification process for the UNI FAST Panel was also initiated.
Also noteworthy is that in 2026 the BACTEROMIC development plan for 2026–2027 was updated, providing for R&D work focused on the UNI FAST, extended UNI FAST, and PBC panels; certification processes in Europe and the United States; the build-out of in-house production capacity; and the launch of system sales. After the reporting period, in early 2026, the first distribution agreements in international markets – in Turkey and Romania – were also signed.
Strong financial base
At the end of 2025, the Group held over PLN 156.9 million in cash, including approximately PLN 63.8 million in investment fund units. In addition, in October 2025, Scope Fluidics conducted a private placement of Series K shares. The shares were subscribed for at an issue price of PLN 145 per share, and the total subscription value exceeded PLN 64 million.
“Developing highly innovative technologies requires stable financial foundations. Our approach is based on prudent capital management, diversification of funding sources, and maintaining an adequate level of cash, which ensures operational flexibility, strengthens our negotiating position, and allows us to pursue our strategic objectives without time or market pressure. In this context, we are currently focusing the majority of our investment activity on the BACTEROMIC project, preparing the company for the planned M&A transaction. 2025 was a period of significant financial strengthening for the Group. Through the Series K share issue, we raised over PLN 64 million gross, which materially increased our financial flexibility. At the end of the year, we maintained sound liquidity, enabling stable financing of operations, further development of key projects, and the achievement of our objectives,” said Szymon Ruta, Vice President and Chief Financial Officer of Scope Fluidics.
In 2026, Scope Fluidics also decided to expand its financing model within Scope Discovery, enabling earlier capital raising at the subsidiary level to accelerate project development and improve risk management. The decision to introduce the expanded model covers, among others, the EDOCERA and HYBOLIC projects. In the Management Board’s view, expanding the financing model will create conditions for the parallel and repeatable development of a greater number of project companies, supporting the achievement of the Group’s strategic objectives.
Project portfolio development
Scope Fluidics continuously works on new initiatives. The unit responsible for initiating and developing new concepts within the Group is Scope Discovery, which operates on the basis of a structured and repeatable project creation process.
At the end of 2025, the Scope Discovery pipeline included 65 initiatives: 28 had already been completed, 11 are under analysis and development, and 24 are awaiting the start of evaluation. Among the Scope Discovery initiatives, two projects – EDOCERA (DSC001) and HYBOLIC (DSC027) – were qualified for development within dedicated project companies.
